Original language | English |
---|---|
Pages (from-to) | 474-485 |
Number of pages | 9 |
Journal | The Lancet Oncology |
Publication status | Published - 2018 |
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
S. De Placido, C. Gallo, M. De Laurentiis , G. Bisagni, G. Arpino, MG. Sarobba, F. Riccardi, A. Russo, L. Del Mastro, AA. Cogoni, F. Cognetti, S. Gori, J. Foglietta, A. Frassoldati, D. Amoroso, L. Laudadio, L. Moscetti, F. Montemurro, C. Verusio, Antonio Bernardo
Research output: Contribution to journal › Article › peer-review